Lexeo Therapeutics shares are trading higher after Raymond James initiated coverage on the stock with a Strong Buy rating and announced a $25 price target.
Lexeo Therapeutics shares are trading higher after Raymond James initiated coverage on the stock with a Strong Buy rating and announced a $25 price target.